AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9821032 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and magneto-optical disk (MOD) recording media
Number of subjects: 119
Study 9821032 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised images of symptomatic plaques
Number of subjects: 119
Study 9821032 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of plaque echolucency
Number of subjects: 119
Study 8129157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg
Number of subjects: 0
Study 8129157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2488911 — intervention group
Group type: EXPERIMENTAL
Intervention: S-Amp (sulbactam plus ampicillin)
Number of subjects: 100
Study 2488911 — intervention group
Group type: COMPARATOR
Intervention: Amp (ampicillin)
Number of subjects: 100
Study 7359644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 32
Study 7359644 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 32
Study 30845335 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid conjugate vaccine
Number of subjects: 20000
Study 30845335 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 20000
Study 27676275 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (2 seasons)
Number of subjects: 40
Study 27676275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no soccer training)
Number of subjects: 40
Study 26194476 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning education program (6 months duration)
Number of subjects: 811
Study 26194476 — intervention group
Group type: COMPARATOR
Intervention: Routine health care services (control group)
Number of subjects: 811
Study 23808885 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention with home-based telehealth equipment and ongoing remote monitoring by a nurse.
Number of subjects: 0
Study 23808885 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group.
Number of subjects: 0
Study 23808885 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention.
Number of subjects: 0
Study 20528880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010
Study 20528880 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010
Study 19474181 — intervention group
Group type: EXPERIMENTAL
Intervention: attend smoking group
Number of subjects: 72
Study 19474181 — intervention group
Group type: EXPERIMENTAL
Intervention: avoid smoking group
Number of subjects: 72
Study 19474181 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 72
Study 17214993 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI‐1067 280 mg qd for 12 months after PCI
Number of subjects: 232
Study 17214993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 17214993 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI‐1067
Number of subjects: 232
Study 15470797 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone administered intravenously
Number of subjects: 9
Study 15470797 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study 11350523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine
Number of subjects: 6
Study 11350523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+1.2% PVP
Number of subjects: 6
Study 11350523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+5% PVP
Number of subjects: 6
Study 11350523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine+10% PVP
Number of subjects: 6
Study 11350523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11350523 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% chlorhexidine
Number of subjects: 6
Study 9077376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 543
Study 9077376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study 9077376 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 543
Study 8339809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1 mg/day
Number of subjects: 154
Study 8339809 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 2 mg/day
Number of subjects: 154
Study 3085789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for two and four weeks
Number of subjects: 11
Study 3085789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for four weeks
Number of subjects: 11
Study 3085789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium etidronate 20 mg/kg/day for two weeks
Number of subjects: 11
Study 11578893 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-O(2) mixture with FGF 0.5 L/min (4/1 ratio)
Number of subjects: 160
Study 11578893 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-O(2) mixtures with FGF < or = 2 L/min
Number of subjects: 160
Study 31164972 — intervention group
Group type: EXPERIMENTAL
Intervention: AAF with synbiotics (prebiotic fructo‐oligosaccharides and probiotic Bifidobacterium breve M‐16V)
Number of subjects: 71
Study 31164972 — intervention group
Group type: COMPARATOR
Intervention: AAF without synbiotics (control)
Number of subjects: 71
Study 28921338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU per week)
Number of subjects: 511
Study 28921338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 26516803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided single-injection infraclavicular block
Number of subjects: 0
Study 26516803 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided double-injection axillary block
Number of subjects: 0
Study 24619917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat co-administered with digoxin
Number of subjects: 40
Study 24619917 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat co-administered with warfarin
Number of subjects: 40
Study 24619917 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 40
Study 24619917 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 40
Study 22515886 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 mL of lidocaine (76.4 mg) with epinephrine plus 0.5 mol/L mannitol
Number of subjects: 106
Study 22515886 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (without mannitol)
Number of subjects: 106
Study 20233195 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional pantoprazole at 192 mg day(-1)
Number of subjects: 120
Study 20233195 — intervention group
Group type: COMPARATOR
Intervention: Infusional pantoprazole at 160 mg day(-1) (40 mg every 6 h)
Number of subjects: 120
Study 20233195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 18068064 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam infusion (0.1 microg/kg/min)
Number of subjects: 193
Study 18068064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 15654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1.0 mg twice daily
Number of subjects: 662
Study 15654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (all doses)
Number of subjects: 662
Study 15654790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 15654790 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg)
Number of subjects: 662
Study 12190178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 86
Study 12190178 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 86
Study 11052040 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based pain management content, education of care providers and patients, and system changes at the point of care
Number of subjects: 118
Study 7634779 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% fragrance mix with 1% sorbitan sesquioleate (SSO)
Number of subjects: 709
Study 7634779 — intervention group
Group type: COMPARATOR
Intervention: 8% fragrance mix without SSO
Number of subjects: 709
Study 7634779 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sorbitan sesquioleate (SSO)
Number of subjects: 709
Study 7634779 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% fragrance mix with 1% SSO
Number of subjects: 709
Study 2106806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 27
Study 2106806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 474334 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Number of subjects: 14
Study 474334 — intervention group
Group type: EXPERIMENTAL
Intervention: Smelling salts
Number of subjects: 14
Study 30395842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU intramuscular injection)
Number of subjects: 76
Study 30395842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 28532200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia with clonidine
Number of subjects: 135
Study 28532200 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 135
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidementia drugs (memantine, donepezil, rivastigmine, galantamine)
Number of subjects: 243
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 243
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 243
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 243
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 243
Study 25391382 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidementia drugs
Number of subjects: 243
Study 23751938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan + spironolactone
Number of subjects: 199
Study 23751938 — intervention group
Group type: COMPARATOR
Intervention: Ambrisentan
Number of subjects: 199
Study 22070741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-lolly
Number of subjects: 92
Study 22070741 — intervention group
Group type: COMPARATOR
Intervention: No ice-lolly (Control)
Number of subjects: 92
Study 19176739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-calcium, low-phytate diet
Number of subjects: 10
Study 19176739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-calcium, high-phytate diet
Number of subjects: 10
Study 19176739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium, low-phytate diet
Number of subjects: 10
Study 19176739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium, high-phytate diet
Number of subjects: 10
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status (SES)
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions that parents support fighting
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive behavior in girls
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of aggression in boys
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliating with aggressive peers (boys)
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliating with aggressive peers (girls)
Number of subjects: 0
Study 17403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of parents' attitudes toward fighting
Number of subjects: 0
Study 15560326 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Condition (pedometers)
Number of subjects: 26
Study 15560326 — intervention group
Group type: COMPARATOR
Intervention: No-feedback Condition (sealed 'disguised' pedometers)
Number of subjects: 26
Study 11330505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact insulin
Number of subjects: 391
Study 11330505 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 391
Study 11330505 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 391
Study 11330505 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoB
Number of subjects: 391
Study 11330505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette years
Number of subjects: 391
Study 9208964 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Arterial Revascularization (IAR)
Number of subjects: 29
Study 9208964 — intervention group
Group type: COMPARATOR
Intervention: Initial Portal Revascularization (IPR)
Number of subjects: 29
Study 7963303 — intervention group
Group type: EXPERIMENTAL
Intervention: Open carpal tunnel release
Number of subjects: 104
Study 7963303 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic carpal tunnel release
Number of subjects: 104
Study 3595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 0
Study 3595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 777
Number of subjects: 0
Study 3595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 10/11
Number of subjects: 0
Study 3595143 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on OCs for at least 3 months)
Number of subjects: 0
Study 3595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil (in women not on OCs at the start)
Number of subjects: 0
Study 3595143 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho 777 and Ortho 10/11 (combined)
Number of subjects: 0
Study 31919502 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum metabolite 2-methoxyacetaminophen sulfate
Number of subjects: 486
Study 31919502 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum metabolite 1-docosahexaenoylglycerophosphocholine
Number of subjects: 486
Study 31919502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic pathway glycine, serine, and threonine metabolism
Number of subjects: 486
Study 31919502 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic pathway Aminoacyl-tRNA biosynthesis
Number of subjects: 486
Study 31710013 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic milk
Number of subjects: 30
Study 31710013 — intervention group
Group type: COMPARATOR
Intervention: Fluoride mouthwash
Number of subjects: 30
Study 28724582 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure pattern of eye involvement without motor automatisms
Number of subjects: 416
Study 28724582 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure semiology features (pause/stare, motor automatisms, eye involvement)
Number of subjects: 416
Study 28724582 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure clusters (presence/absence of eye involvement and motor automatisms)
Number of subjects: 416
Study 25416584 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapulothoracic joint control training exercises
Number of subjects: 40
Study 25416584 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation interventions
Number of subjects: 40
Study 25416584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard rehabilitation interventions and scapulothoracic joint control training exercises
Number of subjects: 40
Study 23724494 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnification sperm isolation for ICSI
Number of subjects: 2
Study 23724494 — intervention group
Group type: COMPARATOR
Intervention: Normal magnification sperm isolation for ICSI
Number of subjects: 2
Study 21387983 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling plus systemic antibiotics
Number of subjects: 29
Study 21387983 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling
Number of subjects: 29
Study 21387983 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling
Number of subjects: 29
Study 19318950 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 19318950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16360199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Z-100 (0.2 microg)
Number of subjects: 221
Study 16360199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Z-100 (40 microg)
Number of subjects: 221
Study 15279498 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine
Number of subjects: 14
Study 15279498 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-containing beverage
Number of subjects: 14
Study 15279498 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (no nicotine)
Number of subjects: 14
Study 15279498 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-containing beverage
Number of subjects: 14
Study 10378565 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic therapy (KT) combined with mechanical percussion (P) using a KT system (Triadyne Kinetic Therapy System; KCI; San Antonio, TX)
Number of subjects: 24
Study 10378565 — intervention group
Group type: COMPARATOR
Intervention: Manual repositioning and manual percussion every 2 h (Control group)
Number of subjects: 24
Study 8777824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (8.5‐10.5 mmol/l)
Number of subjects: 11
Study 1380475 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion during ERCP
Number of subjects: 30
Study 1380475 — intervention group
Group type: COMPARATOR
Intervention: Placebo during ERCP
Number of subjects: 30
Study 1380475 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 30
Study 1380475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6833466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermorphin (5.5 micrograms/kg . min for 30 min)
Number of subjects: 11
Study 6833466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermorphin during naloxone infusion
Number of subjects: 11
Study 6833466 — intervention group
Group type: COMPARATOR
Intervention: D-placebo (0.9% saline)
Number of subjects: 11
Study 31054101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (RT) - 30 Gy in 6 fractions
Number of subjects: 31
Study 31054101 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CHT) - temozolomide 200 mg/m2/day for 5 days every 28 days
Number of subjects: 31
Study 29222362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention units with revised policy allowing pen storage in locking boxes and education provided to nurses
Number of subjects: 8
Study 29222362 — intervention group
Group type: COMPARATOR
Intervention: Control units with no change in policy
Number of subjects: 8
Study 25826322 — intervention group
Group type: EXPERIMENTAL
Intervention: RGN‐259 (0.1%) eye drops, 6 times daily for 28 days
Number of subjects: 9
Study 25826322 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 9
Study 23952850 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening with chest radiography and computer-aided detection
Number of subjects: 1424
Study 23952850 — intervention group
Group type: EXPERIMENTAL
Intervention: Notification of the presence of a lung nodule
Number of subjects: 1424
Study 21422759 — intervention group
Group type: EXPERIMENTAL
Intervention: Human tissue kallikrein with conventional treatment over 12-14 days
Number of subjects: 44
Study 21422759 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 44
Study 19386771 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHENA intervention (coach-led peer-facilitated sessions during sport season)
Number of subjects: 1668
Study 17684876 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 120
Study 17684876 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg plus Droperidol 1.25 mg
Number of subjects: 120
Study 17684876 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg plus Dexamethasone 8 mg
Number of subjects: 120
Study 17684876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 15228025 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacutex dressing (capillary action dressing)
Number of subjects: 0
Study 15228025 — intervention group
Group type: COMPARATOR
Intervention: Assessment by wound area and description
Number of subjects: 0
Study 12361440 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct tape occlusion (applied directly to the wart for a maximum of 2 months)
Number of subjects: 61
Study 12361440 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (liquid nitrogen applied to each wart for 10 seconds every 2-3 weeks for a maximum of 6 treatments)
Number of subjects: 61
Study 10381673 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 serum levels in patients with intermediate uveitis
Number of subjects: 61
Study 10381673 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 and IL-8 levels in intermediate uveitis patients
Number of subjects: 61
Study 8562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaldaride maleate (20 mg four times per day)
Number of subjects: 179
Study 8562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg followed by 2 mg after each unformed stool)
Number of subjects: 179
Study 8562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 179
Study 8562742 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaldaride maleate
Number of subjects: 179
Study 8562742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 2205641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 706
Study 2205641 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 706
Study 2205641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 706
Study 6159902 — intervention group
Group type: EXPERIMENTAL
Intervention: Indanazoline E-VA-16
Number of subjects: 35
Study 6159902 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline
Number of subjects: 35